Fourth-quarter concentration in the metabolome analysis business
First written in FY2016-Q4. 28 of 31 entries say "Restated". Latest entry: FY2025-H1.
Human Metabolome Technologies moved to the "Worse" side of this theme in 2025, 1 year after the typical company in this theme (2024).
The whole theme swung hardest in 2024: 4 of 23 companies on the "Worse" side.
0 other companies' latest entry also says "Reframed".
- FY2025-H1ReframedAnnual report
「Our Group's core business, the advanced research and development support business, tends to generate higher revenue and profit in the second half of the year, which coincides with the fiscal year-end for many customers, as a seasonal factor.」
The explanation was changed from concentration in the third quarter to higher revenue and profit in the second half of the year, which coincides with customers' fiscal year-ends. - FY2024RestatedAnnual report
「As a result, our Group's revenue tends to be concentrated in the third quarter (January to March).」
The seasonal concentration of revenue from the advanced research and development support business in the third quarter, which coincides with customers' fiscal year-ends, continues to be disclosed. - FY2024-Q3RestatedAnnual report
「This was mainly due to an increase of ¥253,986 thousand in accounts receivable resulting from the concentration of revenue in the third-quarter consolidated accounting period, among other factors.」
The seasonal concentration of revenue in the third quarter has been reconfirmed and is also reflected in the increase of ¥253,986 thousand in accounts receivable. - FY2024-Q2RestatedAnnual report
「Our Group's core business, the advanced research and development support business, tends to generate higher revenue and profit during our third-quarter consolidated accounting period, which coincides with the fiscal year-end for many customers, as a seasonal factor.」
The seasonal concentration of revenue and profit from the advanced research and development support business in the third quarter, which coincides with customers' fiscal year-ends, has been reconfirmed. - FY2024-Q1RestatedAnnual report
「Our Group's core business, the advanced research and development support business, tends to generate higher revenue and profit during our third-quarter consolidated accounting period, which coincides with the fiscal year-end for many customers, as a seasonal factor.」
The seasonal concentration of revenue and profit from the advanced research and development support business in the third quarter continues to be disclosed. - FY2023-Q3RestatedAnnual report
「Our Group's core business, the advanced research and development support business, tends to generate higher revenue and profit during our third-quarter consolidated accounting period, which coincides with the fiscal year-end for many customers, as a seasonal factor.」
The seasonal concentration of revenue and profit from the advanced research and development support business in the third quarter continues to be disclosed. - FY2023-Q2RestatedAnnual report
「Our Group's core business, the advanced research and development support business, tends to generate higher revenue and profit during our third-quarter consolidated accounting period, which coincides with the fiscal year-end for many customers, as a seasonal factor.」
The seasonal concentration of revenue and profit from the advanced research and development support business in the third quarter continues to be disclosed. - FY2023-Q1RestatedAnnual report
「Our Group's core business, the advanced research and development support business, tends to generate higher revenue and profit during our third-quarter consolidated accounting period, which coincides with the fiscal year-end for many customers, as a seasonal factor.」
The seasonal concentration of revenue and profit from the advanced research and development support business in the third quarter continues to be disclosed. - FY2022-Q3RestatedAnnual report
「Our Group's core business, the advanced research and development support business, tends to generate higher revenue and profit during our third-quarter consolidated accounting period, which coincides with the fiscal year-end for many customers, as a seasonal factor.」
The seasonal concentration of revenue and profit in the third quarter, which coincides with customers' fiscal year-ends, has been reconfirmed following the change in the business name. - FY2022-Q2RestatedAnnual report
「Our Group's core business, the advanced research and development support business, tends to generate higher revenue and profit during our third-quarter consolidated accounting period, which coincides with the fiscal year-end for many customers, as a seasonal factor.」
The concentration of revenue and profit in the third quarter, which coincides with customers' fiscal year-ends, has been reconfirmed following the change in the business name. - FY2022-Q1RestatedAnnual report
「Our Group's core business, the advanced research and development support business, tends to generate higher revenue and profit during our third-quarter consolidated accounting period, which coincides with the fiscal year-end for many customers, as a seasonal factor.」
The seasonal concentration of revenue and profit in the third quarter, which coincides with customers' fiscal year-ends, has been reconfirmed following the change in the business name. - FY2021RestatedAnnual report
「As a result, our Group's revenue tends to be concentrated in the third quarter (January to March).」
The seasonal concentration of revenue in the third quarter has been reconfirmed following the change in the fiscal year-end. - FY2021-Q3RestatedAnnual report
「Our Group's core business, the metabolomics business, tends to generate higher revenue and profit during our third-quarter consolidated accounting period, which coincides with the fiscal year-end for many customers, as a seasonal factor.」
The concentration of revenue and profit in the third quarter has been reconfirmed as a business characteristic following the change in the fiscal year-end. - FY2021-Q2RestatedAnnual report
「Our Group's metabolomics business tends to generate higher revenue and profit during our third-quarter consolidated accounting period, which coincides with the fiscal year-end for many customers, as a seasonal factor.」
The concentration of revenue and profit in the third quarter has been reconfirmed as a business characteristic following the change in the fiscal year-end. - FY2021-Q1RestatedAnnual report
「Our Group's metabolomics business tends to generate higher revenue and profit during our third-quarter consolidated accounting period, which coincides with the fiscal year-end for many customers, as a seasonal factor.」
The seasonal pattern of higher revenue and profit in the third quarter, which coincides with customers' fiscal year-ends, has been reconfirmed as a business characteristic following the change in the fiscal year-end. - FY2020RestatedAnnual report
「As a result, our Group's revenue tends to be concentrated in the third quarter (January to March).」
The seasonal concentration of revenue in the third quarter has been reconfirmed following the change in the fiscal year-end. - FY2020-Q3RestatedAnnual report
「Our Group's metabolomics business tends to generate higher revenue and profit during our third-quarter consolidated accounting period, which coincides with the fiscal year-end for many customers, as a seasonal factor.」
The seasonal pattern of higher revenue and profit in the third quarter, which coincides with customers' fiscal year-ends, has been reconfirmed as a business characteristic following the change in the fiscal year-end. - FY2020-Q2RestatedAnnual report
「Our Group's metabolomics business tends to generate higher revenue and profit during our third-quarter consolidated accounting period, which coincides with the fiscal year-end for many customers, as a seasonal factor.」
The seasonal pattern of higher revenue and profit in the third quarter, which coincides with customers' fiscal year-ends, has been reconfirmed following the change in the fiscal year-end. - FY2020-Q1RestatedAnnual report
「Our Group's metabolomics business tends to generate higher revenue and profit during our third-quarter consolidated accounting period, which coincides with the fiscal year-end for many customers, as a seasonal factor.」
The seasonal pattern of higher revenue and profit in the third quarter, which coincides with customers' fiscal year-ends, has been reconfirmed as a business characteristic following the change in the fiscal year-end. - FY2019ReframedAnnual report
「Our Group's revenue tends to be concentrated in the third quarter (January to March).」
Following the change in the fiscal year-end, the explanation was changed from concentration in the fourth quarter to concentration in the third quarter (January to March). - FY2019-Q3RestatedAnnual report
「Our Group's metabolomics business tends to generate higher revenue and profit during the fourth-quarter consolidated accounting period, which coincides with the fiscal year-end for many customers, as a seasonal factor.」
The seasonal concentration of revenue and profit from the metabolomics business in the fourth quarter continues to be described. - FY2019-Q2RestatedAnnual report
「Our Group's metabolomics business tends to generate higher revenue and profit during our fourth-quarter consolidated accounting period, which coincides with the fiscal year-end for many customers, as a seasonal factor.」
The seasonal concentration of revenue and profit from the metabolomics business in the fourth quarter continues to be described. - FY2019-Q1RestatedAnnual report
「Our Group's metabolome analysis business tends to generate higher revenue and profit during our fourth-quarter consolidated accounting period, which coincides with the fiscal year-end for many customers, as a seasonal factor.」
The seasonal concentration of revenue and profit from the metabolome analysis business in the fourth quarter continues to be described. - FY2018-Q4RestatedAnnual report
「Our Group's metabolome analysis business tends to generate higher revenue and profit during our fourth-quarter consolidated accounting period, which coincides with the fiscal year-end for many customers, as a seasonal factor.」
The seasonal concentration of revenue and profit from the metabolome analysis business in the fourth quarter continues to be described. - FY2018-Q2RestatedAnnual report
「Our Group's metabolome analysis business tends to generate higher revenue and profit during our fourth-quarter consolidated accounting period, which coincides with the fiscal year-end for many customers, as a seasonal factor.」
The seasonal concentration of revenue and profit from the metabolome analysis business in the fourth quarter continues to be described. - FY2018-Q1RestatedAnnual report
「Our Group's metabolome analysis business tends to generate higher revenue and profit during our fourth-quarter consolidated accounting period, which coincides with the fiscal year-end for many customers, as a seasonal factor.」
The seasonal concentration of revenue and profit from the metabolome analysis business in the fourth quarter continues to be described. - FY2017-Q4RestatedAnnual report
「Our Group's metabolome analysis business tends to generate higher revenue and profit during our fourth-quarter consolidated accounting period, which coincides with the fiscal year-end for many customers, as a seasonal factor.」
The seasonal concentration of revenue and profit from the metabolome analysis business in the fourth quarter continues to be described. - FY2017RestatedAnnual report
「Our Group's revenue tends to be concentrated in the second half of the year, particularly in the fourth quarter.」
The seasonal concentration in the fourth quarter is also described as a full-year business risk. - FY2017-Q2RestatedAnnual report
「Our Group's metabolome analysis business tends to generate higher revenue and profit during our fourth-quarter consolidated accounting period, which coincides with the fiscal year-end for many customers, as a seasonal factor.」
The seasonal pattern of higher revenue and profit in the fourth quarter, which coincides with customers' fiscal year-ends, continues to be described. - FY2017-Q1RestatedAnnual report
「Our Group's metabolome analysis business tends to generate higher revenue and profit during our fourth-quarter consolidated accounting period, which coincides with the fiscal year-end for many customers, as a seasonal factor.」
The seasonal pattern of higher revenue and profit in the fourth quarter continues to be described. - FY2016-Q4First statedAnnual report
「As a seasonal factor, our Group's metabolome analysis business tends to generate higher revenue and profit during our fourth-quarter consolidated accounting period, which coincides with the fiscal year-end for many customers.」
The seasonal pattern of higher revenue and profit in the fourth quarter, which coincides with customers' fiscal year-ends, is described.